Omnipod (Eros) Pod Recall Issued by Insulet Corporation
Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Insulet Corporation is recalling 289,046 Omnipod (Eros) Pods due to potential external soft cannula damage that may cause insulin leakage and under-delivery.
What this FDA recall tells you, and what most readers miss
This notice was issued by FDA on August 8, 2026 and geographically references Worldwide. Its severity classification of "high" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, fda, medical-devices.
What Happened
Insulet Corporation initiated a voluntary recall of Omnipod (Eros) Pods after identifying external soft cannula damage during manufacturing. This defect can result in insulin leaking around the Pod instead of being delivered to the user, leading to potential under-delivery of insulin.
Which Products Are Affected
The recall affects 289,046 units distributed worldwide, including the US and countries such as Austria, Australia, Belgium, Canada, Switzerland, Germany, Denmark, Finland, France, UK, Greece, Israel, Italy, Kuwait, Liechtenstein, Netherlands, Norway, Saudi Arabia, Sweden, and Turkey. Affected products include:
- POD-ZXP425 (10 Pack), POD-ZXP420 (Single Pod) with UDI-DI 20385081120033 (pack) and 10385081120036 (single); Lot L72514
- ZXR425 (10-Pack), ZXR420 (Single Pod); Lots L72516, L72521
- ZXP425 (10 Pack), ZXP420 (Single Pod) with UDI-DI 20385081120033 (pack) and 10385081120036 (single); Lots L72515, L72509, L72513, L72511, L72510, L71480, L72514 Recall number Z-2605-2026; Class I; initiated May 20, 2026.
What You Should Do
Consumers should contact Insulet Corporation for further guidance regarding affected units.
Why This Matters
Failure to deliver insulin properly may result in high blood glucose levels, and in severe cases, diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar syndrome (HHS), or death.
Source
FDA Recall Z-2605-2026 - Insulet Corporation, Acton, MA
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA recall: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,458 characters here).
Similar severity timing
Same severity (high) notices issued closest in time to August 8, 2026.
Frequently Asked Questions
Common questions about this FDA recall.